Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Clinical trial NCT06502977 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06502977
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-27
- Primary completion
- 2025-03-28
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.